DNAtrix Announces Oral Presentation of Positive Overall Survival Data with DNX-2401 in DIPG at the Society for Neuro-oncology (SNO) Annual Meeting

SAN DIEGO, Nov. 22, 2021 /PRNewswire/ -- DNAtrix, a biotech company advancing virus-driven immunotherapies for cancer, today announced that data from the Phase 1 study of DNX-2401 in diffuse intrinsic pontine glioma (DIPG) was presented in an oral presentation at the 26^th Annual Meeting and Education Day of the Society for Neuro-oncology (SNO), which was held from November 18-21, 2021 in Boston, MA. DNX-2401 is an adenovirus-based immunotherapy that is engineered to selectively kill tumor cells and trigger a robust anti-tumor immune response. It has received FDA Fast Track and Rare Pediatric Disease designations for DIPG.

"DIPG is a rapidly progressing tumor with the worst prognosis of any pediatric cancer," said Jeffrey Knapp, chief executive officer of DNAtrix. "Patients receiving conventional radiation therapy typically have a median overall survival of between eight and eleven months, with less than ten percent of the patients reaching the two-year survival mark. The preliminary overall survival data from the DNX-2401 Phase 1 study show a median survival of close to 18 months, with three patients still in follow-up. This is a significant and remarkable impact on overall survival in this difficult-to-treat tumor type, and we look forward to completing the study."

The Phase 1 study evaluated DNX-2401 followed by conventional radiation therapy in 12 newly diagnosed DIPG patients. Tumor reductions were reported for 9 patients (75%), including 3 confirmed (25%) responses per RAPNO criteria. As of the data cutoff, median overall survival was 17.8 months with follow-up ongoing for three patients. No dose-limiting toxicities were observed, and the treatment regimen was well-tolerated.

Oral Presentation Details:

About DNX-2401
DNX-2401 is an oncolytic adenovirus engineered specifically to infect, replicate in, and directly kill cancer cells, as well as elicit a broader anti-tumor immune response. DNX-2401 is currently being evaluated as a potential treatment for highly aggressive brain tumors, including recurrent glioblastoma in adults and newly-diagnosed diffuse intrinsic pontine glioma (DIPG) in children. Clinical studies have demonstrated that DNX-2401 was well tolerated and extended survival for patients with recurrent glioblastoma. DNX-2401 has been granted Fast Track for recurrent glioblastoma and Orphan designation by the FDA and PRIME and Orphan designation by the EMA for high grade glioma, as well as Fast Track and Rare Pediatric Disease designations by the FDA for DIPG.

About DIPG
Diffuse intrinsic pontine glioma (DIPG), also known as diffuse midline glioma, is a rare and highly aggressive infiltrative tumor of the brainstem with the worst prognosis of any pediatric cancer.  No effective treatments are available and novel treatment approaches are needed.

About DNAtrix
DNAtrix is a privately held biotech company developing virus-driven immunotherapies to treat cancer. Its proprietary adenovirus platform is based on an engineered version of the common cold virus that is designed to selectively infect and kill cancer cells while leaving healthy cells unharmed. The company's lead product candidate is DNX-2401, which will enter into a global pivotal Phase 3 clinical study for patients with recurrent glioblastoma. DNX-2401 is also being evaluated in a Phase 1 study for diffuse intrinsic pontine glioma, for which it has received FDA Fast Track and Rare Pediatric Disease designations. A second product candidate, DNX-2440, is in Phase 1 clinical testing in patients with colorectal and other cancers with liver metastasis. The company's investors include Morningside Ventures and Mercury Fund. For more information, please visit the company website at www.DNAtrix.com.

Investor and Media Contacts:
Sylvia Wheeler
Wheelhouse Life Science Advisors
[email protected]

Alexandra Santos
Wheelhouse Life Science Advisors
[email protected]

SOURCE DNAtrix, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED